Arrowhead Pharmaceuticals (ARWR) vs Protagonist Therapeutics (PTGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Protagonist Therapeutics (PTGX) has outperformed Arrowhead Pharmaceuticals (ARWR) over the past year, gaining 114.3% versus a gain of 64.4%. Over five years, PTGX leads with a +351.8% price change compared with -8.2% for ARWR. Protagonist Therapeutics is the larger company by market cap ($9.05 billion vs $8.58 billion), about 1.1 times the size, while Arrowhead Pharmaceuticals is growing revenue faster (+23258.2% vs -89.4%).
Arrowhead Pharmaceuticals converts more of its revenue into profit, with a net margin of -0.2% versus -282.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARWR | PTGX |
|---|---|---|
| Share price | $60.74 | $139.91 |
| Market cap | $8.58B | $9.05B |
| 1-day change | -1.20% | -0.72% |
| YTD return | -8.51% | +60.19% |
| 1-year return | +64.43% | +114.26% |
| 5-year return | -8.19% | +351.76% |
| P/E ratio (TTM) | — | 135.83 |
| EPS (TTM) | $-2.28 | $1.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $829.45M | $46.02M |
| Revenue growth (YoY) | +23258.15% | -89.41% |
| Net income (latest FY) | $-1.63M | $-130.15M |
| Operating margin | 11.86% | -343.63% |
| Net margin | -0.20% | -282.83% |
| 52-week high | $95.49 | $160.81 |
| 52-week low | $34.61 | $65.75 |
| Distance from 52-week high | -36.39% | -13.00% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +76.54% | +24.86% |
| Average volume | 1.91M | 623.06K |
| Shares outstanding | 141.25M | 64.71M |
| Employees | 711 | 141 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PTGX has outperformed ARWR by 49.8 percentage points over the past year.
- Arrowhead Pharmaceuticals is more profitable, keeping -0.2 cents of every revenue dollar as net income versus -282.8 cents for Protagonist Therapeutics.
- Arrowhead Pharmaceuticals grew revenue faster in its latest fiscal year (+23258.15% vs -89.41%).
About Arrowhead Pharmaceuticals
ARWR stock →Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 711 employees
About Protagonist Therapeutics
PTGX stock →Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 141 employees
ARWR vs PTGX FAQ
Which is bigger, Arrowhead Pharmaceuticals or Protagonist Therapeutics?
Protagonist Therapeutics (PTGX) is larger, with a market capitalization of $9.05B compared with $8.58B for Arrowhead Pharmaceuticals (ARWR).
Which stock has performed better over the past year, ARWR or PTGX?
PTGX returned +114.26% over the past 12 months, compared with +64.43% for ARWR (price return, excluding dividends). Past performance does not predict future results.
Are Arrowhead Pharmaceuticals and Protagonist Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.